Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma.
about
Treatment of relapsed and refractory multiple myelomaComparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systemsBortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma.Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathySubcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients.Pharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myeloma.Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.The positive effects of one-hour intravenous administration of bortezomib on peripheral neuropathy in multiple myeloma patientsDevelopment of a brain metastatic canine prostate cancer cell line.Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea.Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trialMarizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trialsThe epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.Bortezomib for previously untreated multiple myeloma.Bortezomib for previously untreated multiple myeloma.Proteasome inhibitors in multiple myeloma: 10 years later.Effective induction therapy with subcutaneous administration of bortezomib for newly diagnosed POEMS syndrome: a case report and a review of the literature.Current therapeutic strategy for multiple myeloma.Efficacy of bortezomib as first-line treatment for patients with multiple myeloma.Bortezomib for the treatment of previously untreated multiple myeloma.Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences.Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits.Treatment-related symptom management in patients with multiple myeloma: a review.Oral ixazomib maintenance therapy in multiple myeloma.Effects of the proteasome inhibitor, bortezomib, on cytodifferentiation and mineralization of periodontal ligament cells.Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells.An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes.Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma.Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.An Overview of Bortezomib-Induced NeurotoxicityTrypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomibActivating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib.A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation.Bortezomib for the treatment of multiple myeloma.
P2860
Q26749180-4869968C-D397-4146-9A9A-9D5D770E071BQ28244352-A5641737-252E-4709-9505-ADBFD728A046Q33410637-04E0E081-A5F2-4D2D-A0EC-9526AEAC6FADQ33422017-853C4723-5AAC-4820-85B6-0C707DC053B0Q33426372-A3986BC8-18F0-47CD-B14E-338BD70F4DF7Q33442798-4F8947AC-0DA1-4448-AB8C-D5F8E188E8AEQ33443001-9E48E4FF-08D6-486A-B18C-8D59E338B05FQ33787025-344B8B33-7459-4C7A-87BE-A36D01A73165Q35116018-71486133-D75C-4E80-88AA-2F3F1A6A6BA3Q35549412-D8ECE68F-CDA8-431D-A513-06999BBEA3F6Q35800851-C2BAF7C0-EC58-4B8A-B575-5E6B4B21C7A0Q36138646-39D0BC66-9157-493E-9338-CCB2C560B349Q37017342-94E26EA4-FF56-4EE2-BD38-F23186EA7CD2Q37166798-406AB217-F542-43B3-AB48-B76BBC610142Q37327280-74A06BB3-4290-4B58-886B-9CBEF4A30866Q37634067-1B8AF661-1C90-4A7B-8E24-8CDDAA9839B8Q37908155-BE3D7574-DC93-4732-A864-2DF19B95225EQ37937699-9FCA0233-CD97-4284-81AC-6804C36500BEQ38014395-96007226-F402-4545-9E45-8D9190D4D1F3Q38061553-F76ABC83-1006-4D89-9C99-78A8548DD0E5Q38072022-4FA25539-6A0C-4EEA-B36E-6B5747ADE43CQ38089497-32A8CFA2-6E25-4F1C-ACEB-BD8ED2194CEBQ38096055-1D06A51A-A96B-4DFC-92CA-F2001E148D8CQ38164689-C6FFF97D-487C-410C-A1A8-A8219CCB9B10Q38218209-8D559755-FF46-42F6-931D-22210B965C44Q38232055-098D3EE4-B255-4208-B23D-F03C2F79937CQ38342281-C0001F48-052B-4590-B013-A14BEBB5EBEBQ38640514-0FBDC4F9-C72B-415E-9B1E-AA6F2BCB1C50Q38982736-1D8AC257-657A-4B15-9AA9-D8259DA521ACQ39377326-AE03E189-6BBA-46E1-A0F5-D7F10F02B8BEQ40261354-C24DDB6E-70BE-43C1-9D96-A98AF4F0DC2EQ41531584-5B04828D-FDF1-4867-844A-7A1D771F57CBQ41607725-8418A82D-1780-40A7-BA40-54E1865DB262Q41849927-ECB1E7BA-B963-4F44-90B6-A4D324BA8E0BQ41856711-722332B4-A66E-42CB-8702-EE291AAC69E1Q42361419-EDD5194D-2C81-4DA3-9E1D-CFC3E779C2BCQ42559886-F0305D5B-9EC2-4D4A-96DB-84D40DBF34CBQ42818861-52A1B1B6-D5A8-4153-897A-3DCB2D58E75BQ45328412-DFE5EC64-6BDC-405E-AD24-69E26F0BBCCDQ47604607-58343BFF-6A67-4847-A552-7E72B5DDB1E8
P2860
Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Prospective comparison of subc ...... atients with multiple myeloma.
@ast
Prospective comparison of subc ...... atients with multiple myeloma.
@en
Prospective comparison of subc ...... atients with multiple myeloma.
@nl
type
label
Prospective comparison of subc ...... atients with multiple myeloma.
@ast
Prospective comparison of subc ...... atients with multiple myeloma.
@en
Prospective comparison of subc ...... atients with multiple myeloma.
@nl
prefLabel
Prospective comparison of subc ...... atients with multiple myeloma.
@ast
Prospective comparison of subc ...... atients with multiple myeloma.
@en
Prospective comparison of subc ...... atients with multiple myeloma.
@nl
P2093
P50
P356
P1433
P1476
Prospective comparison of subc ...... atients with multiple myeloma.
@en
P2093
Helgi van de Velde
Jean-Luc Harousseau
Milin Acharya
Valerie Coiteux
P304
P356
10.3324/HAEMATOL.13285
P577
2008-09-02T00:00:00Z